MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

Core Viewpoint - MiNK Therapeutics, Inc. is set to report its financial results for Q4 and the full year of 2025 on March 31, 2026, and will provide updates on its clinical progress and strategic initiatives in iNKT cell therapies [1][2]. Financial Results Announcement - The financial results will be disclosed before the market opens on March 31, 2026 [1]. - A conference call and webcast will be held at 8:30 a.m. ET on the same day to discuss the results and corporate updates [2]. Recent Developments - MiNK has announced a collaboration with C-Further and the University of Southampton to develop a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers [3]. - This collaboration is expected to provide non-dilutive funding and significant commercial revenue potential, validating MiNK's iNKT platform in engineered cell therapy [3][4]. Strategic Expansion - The collaboration aligns with MiNK's strategy to expand its iNKT platform through clinical-stage programs and engineered cell therapies targeting validated tumor antigens [4]. - The company aims to leverage external partnerships to advance its programs in a capital-efficient manner [4]. Company Overview - MiNK Therapeutics is focused on developing allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators to restore immune balance and enhance cytotoxic responses [6]. - The lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for various conditions, including solid tumors and graft-versus-host disease [7]. - MiNK's pipeline includes TCR-based and neoantigen-targeted iNKT programs, with a scalable manufacturing process aimed at delivering durable and accessible treatments [7].